These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

46 related articles for article (PubMed ID: 3048551)

  • 1. [Influenza vaccination: reinforcement of its effectiveness by combination with an immunostimulant].
    German A; Fattal-German M; Quero AM; Bizzini B
    Bull Acad Natl Med; 1988 Mar; 172(3):467-74. PubMed ID: 3048551
    [No Abstract]   [Full Text] [Related]  

  • 2. Potentiating the effectiveness of influenza vaccination by a combined immunostimulation with P40 immunomodulator: an experimental study in mice.
    Fattal-German M; German A; Bizzini B
    Biomed Pharmacother; 1988; 42(1):73-8. PubMed ID: 3408809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Stimulation of influenza antibody formation following immunization with the use of ascitic tumor].
    Rukavishnikova GE; Alekseeva AK
    Biull Eksp Biol Med; 1975 Feb; 79(2):80-4. PubMed ID: 1093578
    [No Abstract]   [Full Text] [Related]  

  • 4. Protection against influenza virus infection by intranasal vaccine with surf clam microparticles (SMP) as an adjuvant.
    Ichinohe T; Watanabe I; Tao E; Ito S; Kawaguchi A; Tamura S; Takahashi H; Sawa H; Moriyama M; Chiba J; Komase K; Suzuki Y; Kurata T; Sata T; Hasegawa H
    J Med Virol; 2006 Jul; 78(7):954-63. PubMed ID: 16721854
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness.
    Bizanov G; Janakova L; Knapstad SE; Karlstad T; Bakke H; Haugen IL; Haugan A; Samdal HH; Haneberg B
    Scand J Immunol; 2005 Jun; 61(6):503-10. PubMed ID: 15963044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Protection against influenza virus infection by intranasal administration of hemagglutinin vaccine with chitin microparticles as an adjuvant.
    Hasegawa H; Ichinohe T; Strong P; Watanabe I; Ito S; Tamura S; Takahashi H; Sawa H; Chiba J; Kurata T; Sata T
    J Med Virol; 2005 Jan; 75(1):130-6. PubMed ID: 15543590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influenza hemagglutinin vaccine with poly(gamma-glutamic acid) nanoparticles enhances the protection against influenza virus infection through both humoral and cell-mediated immunity.
    Okamoto S; Yoshii H; Akagi T; Akashi M; Ishikawa T; Okuno Y; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2007 Nov; 25(49):8270-8. PubMed ID: 17977633
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A one-size-fits-all flu vaccine?
    Kaiser J
    Science; 2006 Apr; 312(5772):380-2. PubMed ID: 16627732
    [No Abstract]   [Full Text] [Related]  

  • 9. Protective effect of nasal immunization of influenza virus hemagglutinin with recombinant cholera toxin B subunit as a mucosal adjuvant in mice.
    Isaka M; Zhao Y; Nobusawa E; Nakajima S; Nakajima K; Yasuda Y; Matsui H; Hasegawa T; Maeyama J; Morokuma K; Ohkuma K; Tochikubo K
    Microbiol Immunol; 2008 Feb; 52(2):55-63. PubMed ID: 18380802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inactivated influenza H5N1 whole-virus vaccine with aluminum adjuvant induces homologous and heterologous protective immunities against lethal challenge with highly pathogenic H5N1 avian influenza viruses in a mouse model.
    Ninomiya A; Imai M; Tashiro M; Odagiri T
    Vaccine; 2007 May; 25(18):3554-60. PubMed ID: 17293015
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protection of mice with recombinant influenza virus neuraminidase.
    Kilbourne ED; Pokorny BA; Johansson B; Brett I; Milev Y; Matthews JT
    J Infect Dis; 2004 Feb; 189(3):459-61. PubMed ID: 14745703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective immunity against influenza H5N1 virus challenge in mice by intranasal co-administration of baculovirus surface-displayed HA and recombinant CTB as an adjuvant.
    Prabakaran M; Velumani S; He F; Karuppannan AK; Geng GY; Yin LK; Kwang J
    Virology; 2008 Oct; 380(2):412-20. PubMed ID: 18786689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoenhancing agents in prevention and treatment of influenza and other viral respiratory infections.
    Ganguly R; Khakoo R; Spencer JC; Waldman RH
    Dev Biol Stand; 1977 Jun 1-3; 39():363-72. PubMed ID: 75118
    [No Abstract]   [Full Text] [Related]  

  • 14. [Further immunity tests on a mouse-lethal influenza virus strain Hong Kong with reference to its subtype. II].
    Herzberg K
    Zentralbl Bakteriol Orig; 1971; 216(4):421-7. PubMed ID: 5088345
    [No Abstract]   [Full Text] [Related]  

  • 15. Epidermal powder immunization: cellular and molecular mechanisms for enhancing vaccine immunogenicity.
    Chen D; Burger M; Chu Q; Endres R; Zuleger C; Dean H; Payne LG
    Virus Res; 2004 Jul; 103(1-2):147-53. PubMed ID: 15163503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.
    Eliasson DG; El Bakkouri K; Schön K; Ramne A; Festjens E; Löwenadler B; Fiers W; Saelens X; Lycke N
    Vaccine; 2008 Feb; 26(9):1243-52. PubMed ID: 18243429
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poly(gamma-glutamic acid) nano-particles combined with mucosal influenza virus hemagglutinin vaccine protects against influenza virus infection in mice.
    Okamoto S; Matsuura M; Akagi T; Akashi M; Tanimoto T; Ishikawa T; Takahashi M; Yamanishi K; Mori Y
    Vaccine; 2009 Sep; 27(42):5896-905. PubMed ID: 19647814
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaxfectin, a cationic lipid-based adjuvant for protein-based influenza vaccines.
    Hartikka J; Bozoukova V; Yang CK; Ye M; Rusalov D; Shlapobersky M; Vilalta A; Wei Q; Rolland A; Smith LR
    Vaccine; 2009 Oct; 27(46):6399-403. PubMed ID: 19552895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vaccination will work better than culling, say bird flu experts.
    Butler D
    Nature; 2005 Apr; 434(7035):810. PubMed ID: 15829925
    [No Abstract]   [Full Text] [Related]  

  • 20. Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.
    Wu F; Yuan XY; Huang WS; Chen YH
    Vaccine; 2009 Oct; 27(43):6095-101. PubMed ID: 19056447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.